Page 12 - Read Online

Page 309 Zhang et al. J Transl Genet Genom 2024;8:302-11 https://dx.doi.org/10.20517/jtgg.2024.39

DECLARATION
Authors’ contributions
Concept and design of the review,and drafting: Zhang D
Literature collection: Xie K
Revising the manuscript: Zhang J
All authors read and approved the final version of the manuscript.

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
The Author(s) 2024.

REFERENCES
1. Vardarli I, Rischpler C, Herrmann K, Weidemann F. Diagnosis and screening of patients with Fabry disease. Ther Clin Risk Manag
2020;16:551-8. DOI PubMed PMC
2. Linhart A, Germain DP, Olivotto I, et al. An expert consensus document on the management of cardiovascular manifestations of Fabry
disease. Eur J Heart Fail 2020;22:1076-96. DOI
3. Battaglia Y, Fiorini F, Azzini C, et al. Deficiency in the screening process of Fabry disease: analysis of chronic kidney patients not on
dialysis. Front Med 2021;8:640876. DOI PubMed PMC
4. Germain DP, Altarescu G, Barriales-Villa R, et al. An expert consensus on practical clinical recommendations and guidance for
patients with classic Fabry disease. Mol Genet Metab 2022;137:49-61. DOI
5. Germain DP, Fan JQ. Pharmacological chaperone therapy by active-site-specific chaperones in Fabry disease: in vitro and preclinical
studies. Int J Clin Pharmacol Ther 2009;47 (Suppl 1):S111-7. PubMed
6. Najafian B, Svarstad E, Bostad L, et al. Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients
with Fabry disease. Kidney Int 2011;79:663-70. DOI PubMed PMC
7. Tøndel C, Bostad L, Hirth A, Svarstad E. Renal biopsy findings in children and adolescents with Fabry disease and minimal
albuminuria. Am J Kidney Dis 2008;51:767-76. DOI PubMed
8. Kurdi H, Lavalle L, Moon JCC, Hughes D. Inflammation in Fabry disease: stages, molecular pathways, and therapeutic implications.
Front Cardiovasc Med 2024;11:1420067. DOI PubMed PMC
9. Mehta A, Clarke JT, Giugliani R, et al; FOS Investigators. Natural course of Fabry disease: changing pattern of causes of death in FOS
- Fabry outcome survey. J Med Genet 2009;46:548-52. DOI
10. Wanner C, Oliveira JP, Ortiz A, et al. Prognostic indicators of renal disease progression in adults with Fabry disease: natural history
data from the Fabry registry. Clin J Am Soc Nephrol 2010;5:2220-8. DOI PubMed PMC
11. Echevarria L, Benistan K, Toussaint A, et al. X-chromosome inactivation in female patients with Fabry disease. Clin Genet
2016;89:44-54. DOI
12. Řeboun M, Sikora J, Magner M, et al. Pitfalls of X-chromosome inactivation testing in females with Fabry disease. Am J Med Genet A
2022;188:1979-89. DOI
13. Zhang D, Zhang J, Liang S, Wang J, Liu Z. Clinic-pathologic features and renal outcome of Fabry disease: data from a Chinese cohort.
Am J Nephrol 2018;48:137-46. DOI
14. Svarstad E, Marti HP. The changing landscape of Fabry disease. Clin J Am Soc Nephrol 2020;15:569-76. DOI PubMed PMC